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ABSTRACT 
SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND BONE MINERAL 
DENSITY IN A POPULATION OF U.S. PREMENOPAUSAL WOMEN 
MAY 2011 
LORI J PETERSON, BA, UNIVERSITY OF MASSACHUSETTS, BOSTON 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Elizabeth R. Bertone-Johnson 
 
Low bone mineral density (BMD) in post-menopausal women is a risk factor for 
bone fractures and osteoporosis development.  Prior studies in post-menopausal women 
have shown the use of antidepressant medications, specifically selective serotonin 
reuptake inhibitors (SSRIs) to be inversely related to BMD. However, the association has 
not been studied in pre-menopausal women.  Current SSRI use is widespread with 8% of 
U.S. women age 18-44 reporting use.  We evaluated the association between SSRIs and 
BMD and bone mineral content (BMC) cross-sectionally using data from the University 
of Massachusetts Vitamin D Status Study. SSRI use, diet, and lifestyle factors were 
assessed by questionnaire. BMD and BMC were measured using dual-energy x-ray 
absorptiometry (DEXA).  The study included 256 women aged 18-30 (mean=21.6 years, 
SD=4.3 years). In this population, SSRI use was 5%, BMD values ranged from 0.97-1.38 
g/cm2 (mean 1.16, SD 0.08), and BMC values ranged from 1833g to 3682g (mean 
2541.5, SD=349.2). After adjustment for age, body mass index, and physical activity, 
mean BMD in the 13 users of SSRIs was 1.15g/cm2 (SD=0.06) compared to 1.16g/cm2 
(SD=0.77) in the 243 non-users (p =0.66).   After the same adjustments, mean BMC in 
 vi 
 
the 13 users was 2467.1g (SD=285.0) compared to 2547.6g (SD=352.6) in the 243 non-
users (p=0.94).  Our findings do not support an inverse association between SSRI use and 
BMD or BMC.  However, given the prevalence of SSRI use in young women and the 
potential for adverse effects on bone health, further study of this association is warranted.   
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 CHAPTER I 
 
INTRODUCTION 
 
 Low bone mineral density (BMD), also known as osteopenia, is a condition 
defined by the World Health Organization (WHO) as a change in BMD of between 1 
standard deviation (SD) and 2.5 SD below the mean BMD of a healthy young adult.10  In 
2005, an estimated 49% of post-menopausal women met the WHO definition of low 
BMD, translating to 22.7 million women over the age of 50 with the condition.10 Low 
BMD is a risk factor for future development of fractures and osteoporosis in older 
populations.11   These conditions are projected to affect 14 million U.S. men and women 
and cost nearly 25 billion dollars per year.5  
 There are no statistics available on the prevalence of low BMD in premenopausal 
women, specifically those women age 18-30.  Women in this age category are thought to 
have achieved peak bone mass.  However, depression and anorexia nervosa have been 
shown to negatively affect BMD.5, 16   According to the National Institutes of Mental 
Health, depression is most common in women aged 25-44 and anorexia is most common 
in women aged 15-19 with a prevalence of 0.5-1%. 16 These conditions are both treated 
with antidepressant medications.  The most widely used class of antidepressants in the U. 
S. is known as selective serotonin reuptake inhibitors or SSRIs.  Indeed, up to 8% of 
women, aged 18-44, in the U.S. report using this class of medications.19   
 SSRIs work by inhibiting the reuptake of serotonin in the central nervous system, 
effectively blocking the serotonin transporter and making more serotonin available to the 
central nervous system and potentially relieving the symptoms of depression.7   The 
mechanism for how SSRI use leads to low BMD is unclear.7   However, recent 
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experimental studies have discovered serotonin receptors and transporters in the bones of 
chickens and mice.2, 20, 21 Serotonin and its transporters are believed to enhance fibroblast 
cell proliferation, increase activity in clonal osteoblasts, and alter the intensity in the 
response of osteoblasts to stimulation.20 If the inhibitory action of SSRIs leads to a 
reduction in osteoblast activity and a reduction in the coupling activity of osteoblast and 
osteoclasts, this could be the mechanism by which SSRI use leads to low BMD. 8    
There have been no studies that have evaluated the effect of SSRI use on BMD in 
women ages 18 to 30.  However, the association has been studied in post-menopausal 
women and men.  Three prospective cohort studies, 15, 17, 18 four cross-sectional studies, 3, 
9, 11, 22
 and one longitudinal study 6   have been conducted.  Use of SSRIs increased the 
risk of low BMD in all but two11, 18 of these studies.  The age range for the studies was 
54-82 years of age with only the Third National Health and Nutritional Examination 
Survey (NHANES III) 11 including women as young as 29, however still above college 
age. 
 Because there is evidence supporting the association between SSRI use and low 
bone mineral density in older women, and low BMD is an established risk factor for 
fractures and osteoporosis, it is important to determine if using SSRIs earlier in life also 
leads to earlier negative effects on BMD.  Such findings would identify an earlier 
predictor of fractures and osteoporosis.  We conducted a cross-sectional analysis of SSRI 
use and BMD using data from the University of Massachusetts Vitamin D Status Study 
conducted among women aged 18-30. 
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CHAPTER II 
PHYSIOLOGY OF SSRIS AND BONE MINERAL DENSITY 
 The biological mechanism for how SSRI use could lead to low BMD is not well 
understood, 8   however there are several possible pathways. Understanding how the 
medication works and how it is related to bone mineral density requires understanding 
how serotonin works in the body, its specific cell processes, and recognition of new 
evidence for serotonin pathways in bone.   
 In the central nervous system, serotonin is responsible for regulating behavioral, 
physiological, and cognitive functions.14   Serotonin synthesis begins with an uptake of 
an amino acid called tryptophan.  Tryptophan is taken into the neuron and through 
enzymatic action is transformed into serotonin.4   Serotonin is accumulated by the 
vesicular monoamine transporter 2 (VMAT2), which assists the neurons in the release of 
neurotransmitters. Serotonin is then stored in neural vesicles until it is needed and 
released by the vesicles.  Once released the serotonin action can be stopped by the 
reuptake action of serotonin transporters.4   SSRI antidepressant medications act in a 
similar manner by inhibiting the transporter, 6 leading to an increase in the level of extra-
cellular serotonin in the central nervous system and thereby decreasing the depressive 
symptoms in patients.7  
 The mechanism by which SSRI may impact BMD is suggested by the finding that 
functional serotonin receptors and transporters have been identified in the bone of 
chickens and mice.2, 20, 21 Serotonin is thought to aid in some functions of the osteocytes 
and assist in remodeling and repair of bone through osteoblast cell proliferation.20 The 
main action of SSRI’s is to block the serotonin transporters and increase the level of 
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extra-cellular serotonin. 7   The blocking of serotonin transporters in the central nervous 
system may help to alleviate symptoms of depression; however in the skeletal system this 
same action may lead to a reduction in osteoblast activity and a reduction in the coupling 
activity of osteoblasts and osteoclasts, both necessary for bone remolding. Once there is 
insufficient serotonin to carry out these necessary functions, the bones may be unable to 
complete remolding and adverse changes in bone density may be seen.    
 In summary, the actual pathways by which SSRI’s lead to low BMD are not well 
understood.  Recent identification of serotonin receptors and transporters in osteoblasts 
and osteocytes suggests a possible mechanism.  However, further research is needed to 
fully understand the biological mechanism and its potential implications.  
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CHAPTER III 
EPIDEMIOLOGY OF SSRIS AND BONE MINERAL DENISTY 
 The epidemiological evidence for the association between SSRI use and low 
BMD is limited with only seven observational studies conducted.6, 9, 11, 15, 17, 18, 22   
Previously, several studies have evaluated SSRI use in conjunction with the association 
between depression and low bone mineral density, 3, 6, 9, 11, 15, 17, 18, 22   or in conjunction 
with  an association between depression and risk of fractures, 17, 18 Among the studies 
focusing on SSRI use and low BMD, two included only older men, 3, 9   three included 
male and female participants, 11, 15, 17   and three focused on women only.6, 18, 22 Overall 
the findings have been consistently positive for an inverse association between SSRI use 
and BMD with four of the studies finding an increased risk of low BMD, 6, 9, 17, 22 two 
studies finding no association, 11, 18 and one study finding an increased risk for women 
but not for men.15 
 The three studies in women focused on post-menopausal women age 42-82 and 
shared several methodological aspects.  First, all studies measured BMD using a Dual 
Energy X-ray Absorptiometry scanner (DEXA).  Second, all studies adjusted for 
depression.  Third, SSRI use was determined by asking women to bring their current 
medication to the interview, where the medication was typed, recorded, and subsequently 
confirmed by medical personnel.  Forth, all measured BMD at specific sites, including 
femoral neck, mid forearm, trochanter, and total body. Finally, each study adjusted for 
the following covariates: age, race, weight, height, smoking, calcium use, menopausal 
status, health status, and physical activity.  
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 In the first of these studies, Williams et al.22   conducted a cross-sectional analysis 
of 128 women aged 42-61 in the Geelong Osteoporosis Study in South Eastern Australia 
between the years 1994-1997.  Women included in the analysis had a lifetime history of 
depression as measured by the research version of DSM-IV-TR structured clinical 
interview.  For those women who used SSRIs compared to those who do not and at each 
BMD site measured, the researchers found a lower percent of BMD:  femoral neck was 
5.6% lower, [0.977 (0.116) vs. 0.922 (0.117) p=0.03], trochanter was 6.2% lower, [0.813 
(0.105) vs. 0.763 (0.107) p=0.04], and mid forearm was 4.4% lower, [0.745 (0.007) vs. 
0.712 (0.068) p=0.03]. The strength of the study was adjusting for depression as a 
confounder.   
 Diem et al.6 conducted a longitudinal study among 2,722 women aged 74-82 from 
the Study of Osteoporotic Fractures (SoOF) during the years 1997-1999.  The study was 
conducted in four U. S. sites including; Maryland, Minnesota, Oregon, and Pennsylvania.  
In addition to the above listed covariates the study also adjusted for vitamin D intake, 
ability to rise from a chair, walking speed, use of oral estrogens, use of thiazide, 
bisphosphonate, and mini-mental state exam.  Among users of SSRIs there was a 1.6 
times greater rate of loss in BMD in all sites scanned, compared to non-users of SSRIs. 
The mean adjusted rate of bone loss per year for users at total hip was [-0.82% (95% CI=-
1.00, -0.64)], at the femoral neck was [-0.60% (95% CI=-0.84, -0.36)] and at trochanter  
[-0.93% (95% CI=-1.18, -0.68)]. The strength of the study was the adjustment for 
depression and estrogen use; both have been theorized to play a role in bone health. 
 Spangler et al. conducted a prospective cohort study of women aged 50-79, 
enrolled in the Women’s Health Initiative Study during 1994-1998.  BMD measures were 
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collected on a subgroup of participants (14%) at baseline.  Only those women who had 
complete information on at least one site were included in the analysis (hip=4539, 70% 
spine=4417, 69% total body=4502, 69%).  This study examined use of SSRIs 
exclusively.  The authors found no association between the use of SSRIs and 3-year 
changes in BMD.18 [.003 (-0.0005 to .0069) p=0.09], [.002 (-.0031 to .0078) p=0.40], 
[.003 (-0.0007 to .0073) p= 0.10] in hip BMD, spine BMD, and total body BMD, 
respectively, compared with nonusers.  
In summary, several studies have examined the association between SSRI use and 
BMD in women.  Two of these three studies found that SSRI use increased the risk of 
adverse changes to BMD. No studies have examined the association in a population of 
young women aged 18-30.   
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CHAPTER IV 
SUMMARY 
 Low BMD is a known risk factor for the development of fractures and 
osteoporosis. Low BMD is highly prevalent in older populations; with 49% of 
postmenopausal women meeting the WHO criteria.10 SSRIs are widely used in young 
women age 18-30 with nearly 8% reporting use.  It is unknown whether use of SSRIs 
affects BMD in young women at or near peak bone mass. 
 Recently, receptors and transporters for serotonin have been identified in bone, 2, 
20, and 21 leading to the hypothesis that the inhibitory action of SSRIs may have an adverse 
effect on bones.7 
 Three epidemiological studies have focused on the relationship between SSRI use 
and BMD in women.  Of these studies, two have found an increased risk and one 
observed a null finding.  No epidemiological studies have examined the relationship in 
women age 18-30.   
 Therefore, we studied the association between SSRI use and BMD in women age 
18-30, with a cross-sectional analysis of the data from the University of Massachusetts 
Vitamin D Status Study.  We proposed that there is a negative association between SSRI 
use and BMD in this population.  
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CHAPTER V 
HYPOTHESIS AND SPECIFIC STUDY AIM 
 Using a cross-sectional study design, the goal of this study was to determine if 
there is an association between the use of SSRI medications and changes in BMD among 
premenopausal U.S. women aged 18-30.  
 Using the same study data we conducted a secondary analysis of the relationship 
between history of depression and BMD.   
  Hypothesis 1: Women who use SSRI medication have lower BMD or BMC 
compared with women who do not use SSRI medication.   
 Hypothesis 2: Women who have a history of depression have lower BMD 
compared with women who do not have a history of depression. 
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CHAPTER VI 
METHODS  
VI. A. Study Design and Population 
 We conducted a cross-sectional study of SSRI use and BMD using data collected 
from the University of Massachusetts Vitamin D Status Study.  The Vitamin D Status 
Study began in March of 2006 and is on-going. This analysis utilized data collected from 
participants enrolled as of February 2011.  To be eligible, study participants had to be 
female, age 18-30, premenopausal, menstruating regularly, and residing in the local area 
surrounding the University of Massachusetts, Amherst, MA.1  For the purposes of this 
analysis we used the previously defined exclusions.   Women were ineligible if the 
reported any of the following conditions: high blood pressure, elevated cholesterol, 
kidney disease, liver disease, osteomalacia, digestive disorders, rheumatologic disease, 
multiple sclerosis, thyroid disease, hyperparathyroidism, cancer, diabetes, or polycystic 
ovaries. 20   Women with a history of using any of the following medications were also 
excluded: corticosteroids, anabolic steroids, anticonvulsants, cimetidine, and propranolol.  
Because the purpose of these exclusions is to focus the effect of SSRI medication only, 
we excluded those women who reported use of antidepressants other than SSRIs.  These 
include: monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, tranquilizers, 
and lithium.  The following brands were considered SSRIs for our analysis: Prozac, 
Zoloft, Paxil, or Effexor.  In addition, if a study participant did not have a completed 
DEXA scan, she was excluded. DEXA scans were not available in the very early months 
of the study and therefore resulted in the exclusion of 10 women.  
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 Eligible participants were scheduled to complete all study requirements in a single 
visit.  In both phases of the study, the visit was required to occur during the luteal phase 
of each woman’s menstrual cycle.25   However, since the timing of ovulation is not 
relevant to the use of SSRIs or bone mass we did not consider luteal phase in the current 
analysis.  During the visit, the women completed a questionnaire assessing lifestyle 
factors, a modified version of the Harvard Food Frequency Questionnaire (FFQ), 
provided a blood sample, and received a total body DEXA scan to measure BMD and 
bone mineral content (BMC).1, 25  
VI. B. Assessment of Exposure 
 We measured the use of SSRIs with a self-administered questionnaire.  One 
question was used to determine if the women were currently using SSRIs.  The question 
was: “Are you currently taking any of the following medications?  Mark all that apply.”  
SSRI was the second choice on the list.  Those women who marked “yes” to the SSRI 
choice were considered exposed.  A women could have marked “yes” to SSRIs and “yes”  
to either “use of antacids” or “other medications” and still be considered exposed as long 
as the other medication was not another type of antidepressant, an anticonvulsant, a 
tranquilizer, or lithium.  If a woman marked one of the following choices alone she was 
considered unexposed: “not taking any medications”, “tranquilizers”, “migraine 
prevention”, or “other medication”. In this analysis, current use of SSRIs was 
dichotomized as use or no use. 
 We measured history of depression using the same self-report questionnaire.  The 
women were asked if they had ever been clinician-diagnosed with depression.  If the 
women answered “yes” they were considered exposed.   
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VI. C. Validity of the Exposure Assessment 
 Self-report for antidepressant medications, including SSRIs, was previously 
validated by Kwon et al.12 using pharmacy claims as the gold standard.  The study 
participants lived in the Boston, MA area and were recruited from one of 9 area medical 
centers.  The authors used 3 measures of antidepressant use.  The first two measures were 
the following questions; “Do you now take any prescription medicines for depression?” 
and “Are you now taking prescription medicine for depression?”  The data on pharmacy 
claims was obtained through access to medical records via Tufts Health Plan.  
Antidepressant use was defined as “the appearance of any claim for an antidepressant 
within the 90 days preceding a patient survey date.”  Self-report and pharmacy claims 
matched in 85% of cases with a kappa of 0.69.  
VI. D. Assessment of Outcome 
 BMD and bone mineral content (BMC) were measured using total body DEXA 
scans.  BMC was analyzed as another measure of bone health in the participants.  Due to 
the age group, our population is at or near the peak levels of BMD; therefore, we 
determined the mean differences in BMD and BMC across the population.  BMD was 
measured in g/cm2   and reported as the areal BMD.  Areal BMD refers to the surface area 
of the bone.  This is in contrast to using bone mineral apparent density (BMAD), which 
measures volume of the bone.  BMC was measured in grams and reported as the total 
bone content.  The DEXA scanner is a narrow angle fan GE Lunar Prodigy scanner (GE 
Lunar Corp. Madison, WI), which was calibrated daily according to manufacturer 
instructions and all scans were carried out by two, trained technicians.  All scans were 
analyzed using the manufacturer provided enCORE 2002 software, version 6.80.002.25   
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VI. E. Validity of Outcome Assessment 
 The validity of DEXA scans to measure BMD and BMC has been established in 
numerous studies.3, 9, 11 In addition, DEXA is used by the Centers for Disease Control and 
Prevention (CDC), as part of the National Health and Nutrition Examination Survey 
(NHANES) studies.11 Melton et al. found the correlations between whole body sites 
versus site-specific were good for most sites with the correlation between total body and 
site-specific as follows:  1) spine r2=0.84; 2) Lumbar spine r2=0.93;  3) Pelvis region 
r2=0.74. 14 
VI. F. Assessment of Covariates 
 Information on lifestyle, demographic, and potential risk factors was collected 
using a self-report questionnaire completed at the same time as the DEXA scans, food 
frequency questionnaires, and SSRI use.  We collected information on the following 
variables: history of depression, oral contraceptive use, age, smoking, alcohol 
consumption, race, age at onset of menstruation, and prior pregnancies.  The amount of 
physical activity per week was calculated for each woman based on answers to several 
questions on the lifestyle questionnaire. A total physical activity score was obtained and 
reported as MET-hours per week of activity.1  Calcium and vitamin D intake were 
assessed using FFQ (a modified version of the Harvard FFQ).  Finally we collected 
height and weight information from the women and calculated her BMI (BMI=weight 
(kg)/height (m2)).   
VI. G. Univariate Analysis 
 All analyses were performed using SAS software version 9.2, (SAS Institute Inc, 
Cary, North Carolina.)   
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The frequency and percent of subjects based on distribution of SSRI use was 
calculated, as well as the distribution of the mean and SD of BMD and BMC in the 
population.   
VI. H. Bivariate Analysis 
 We cross-tabulated the covariates by the exposure and the outcome to identify any 
potential confounders.  For exposure by continuous variables (i.e. age, BMI, physical 
activity, BMD, calcium, and vitamin D) mean and standard deviations were calculated, 
and for exposure by categorical variables (parity, alcohol use, current oral contraceptive 
use, current smoking, tertiles of calcium and vitamin d use, dichotomized vitamin D use, 
history of depression, and dichotomized age at menarche) we calculated frequencies, 
relative frequencies, percents, and p-values from Fisher’s Exact tests due to our small cell 
counts. 
For outcome by continuous variables, we calculated differences in BMD per one 
unit change in the continuous covariate along with standard errors (SE) using general 
linear models.  For outcome cross tabulated with categorical variables, means and SDs 
were calculated using one way ANOVAS.  Differences in the distributions are presented 
by p-values from a two-sided t test. 
VI. I. Multivariate analysis 
 We conducted three separate analyses.  In the first we determined the relationship 
between SSRI use and BMD.  In the second we determined the relationship between 
SSRI use and BMC, in the third we looked at history of depression as a predictor of BMD 
in the population.  All analyses were conducted using linear regression models.  Any 
potential confounders were included in the final model if the change between the 
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unadjusted and adjusted β-coefficient was 10% or more.  Final, fully adjusted mean 
differences in BMD and BMC were calculated using least squares methods.     
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CHAPTER VII 
HUMAN SUBJECT PROTECTION 
 All study participants signed a written informed consent prior to enrolling in the 
study and any collection of data.  The women read the consent form in the presence of 
study staff and were given opportunity to express their concerns.  If the participant agreed 
then she and the staff member both signed the consent form.  All signed consent forms 
were stored at the study center in a binder.  
 Each study participant’s personal information is kept confidential in the following 
manner: subject name and contact information are stored in files separately from study 
data.  Subjects were given a study identification number and it is this number that 
accompanies all participant information.  Any study information that is stored on a 
computer is password protected.  No identifying information was or will be published in 
the future.  Access to study data is restricted to the primary investigator and study staff. 
All study staff underwent institutional review board confidentiality training prior to 
accessing data.   
 The risks to the participants were minimal with only the slight pain or bruising 
associated with a needlepoint injection, from the blood draw.   There is a minimal risk of 
infection from the needle stick, although this should be minimized by the use of single-
use equipment.  The low-dose radiation from the DEXA scanner is minimal, equivalent 
to the dose received from an airplane trip from Boston to Los Angeles, CA.   
 We conducted non-beneficial research, or research with no therapeutic benefit to 
the study participants.  However, the women received information on the density of their 
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bones, fat mass, body composition, and vitamin D levels.  This may highlight for them 
any medical issues and perhaps lead to beneficial lifestyle changes.  
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CHAPTER VIII 
PERMISSION TO ACCESS DATA 
I, Lori J Peterson, have completed and passed the Human Subject’s Training 
through the Collaborative Institutional Training Initiative (CITI) registered with the 
University of Massachusetts Amherst.  I have been granted permission to access the 
UMass Vitamin D Status Study by the Co-Principle Investigator, Elizabeth Bertone-
Johnson, for the purpose of this thesis.   
Signed: 
 
_________________________ 
Dr. Elizabeth Bertone-Johnson 
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CHAPTER IX 
RESULTS 
 In this population of pre-menopausal women the average age was just over 
21 years (mean 21.6 years, SD=4.28 years (Table 1)).  Most women averaged a low 
amount of daily physical activity and  were in the normal range of BMI (mean 22.99 
kg/m², SD=3.29).  Most women also had levels of calcium intake below the 
recommended daily intake of 1300mg and levels of vitamin D intake below the daily 
recommended intake of 20ng/ml. (78% and 85% respectively).  Additionally, few women 
had been pregnant (3%), were heavy alcohol consumers (23%), or were smokers (5%), 
The majority of participants considered themselves to be white race (86%), had not 
previously suffered from depression (87%), and were younger than 14 at menarche 
(79%). 
Self-reported use of SSRI medications was low with only 13 or 5% of study 
participants reporting use (Table 2).  The mean BMD of the population was 1.16 g/cm² 
(0.08) (Table 3), with a range of 0.97g/cm² to 1.38 g/cm².  The distribution of BMC had a 
mean of 2541.5g (349.2) with a range of 1833g to 3682g.  At the onset of the study in 
2006, 10 women were enrolled prior to the availability of the DEXA scanner; as a result 
these ten (4%) women were unable to complete the scans and were therefore not included 
in the analysis.  
Women who reported using SSRIs were not significantly different from those not 
using the medication with respect to age, BMI, physical activity, calcium or vitamin D 
intake, having been pregnant, use of contraceptives, race, or age at menarche (Table 4).  
However, users and non-users were significantly different with respect to history of 
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depression, with 85% of SSRI users reporting depression compared to only 10% of 
nonusers (p=<.001).   
 BMI and physical activity were the most statistically significant predictors of 
BMD (Table 5). For each one unit (kg/m²) change in BMI, BMD was .009g/cm² higher 
(SE=0.0014, p=<.0001), and for every one unit (1 hour of METS per week) change in 
physical activity BMD was 0.0002g/cm² higher, (SE=0.00007, p=0.0007).   History of 
pregnancy, use of alcohol, current smoking or contraceptive use, race, various intake 
levels of calcium or vitamin D, history of depression, or age at menarche were not 
associated with BMD. BMI and physical activity were positively associated with BMC 
(Table 6).  For every one unit (kg/m²) change in BMI, BMC was 45.6g higher, (SE=6.12, 
p=<.0001), and for every one unit (1 hour of METS per week) change in physical activity 
BMC was a 0.8g higher, (SE=0.33, p=0.02).   
 In unadjusted models estimating the relationship between SSRI use and BMD 
(Table 7), mean BMD in SSRI users (1.16 g/cm², SD=0.06) did not differ significantly 
from non users (1.17 g/cm² SD=0.08), (p=0.78). In unadjusted models mean BMC in 
SSRI users did not differ significantly from non users (2549.5g, SD=285) compared with 
(2541.1g SD=352.6) in non-users, (p=.94).     
 In analysis adjusted for age, SSRI use remained not associated with BMD or 
BMC (table 8).  Results further adjusted for BMI and physical activity were similar for 
each outcome.  The adjusted mean BMD in users of SSRIs was 1.15g/cm² and non-users 
was 1.16g/cm², (p=0.66). Use of SSRIs was associated with a -0.0094g/cm² lower bone 
mineral density. The adjusted mean BMC in users was 2467.1g and in non-users was 
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2547.6g, (p=0.39). Use of SSRIs was associated with a -80.4g lower bone mineral 
content.  
 In a secondary analysis estimating the association between history of depression 
and BMD and BMC, 33 (12.9%) women reported a history of depression (Table 9). The 
mean BMD for women with a history of depression was 1.17g/cm² (SD=0.08) compared 
to 1.16g/cm² (SD=0.08) in women without.  In unadjusted and models adjusted for age, 
BMI, and physical activity there was no evidence of an inverse relationship between 
history of depression and BMD, (p=0.29) (Table 10).  History of depression was 
associated with a 0.015g/cm² lower bone mineral density.  
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CHAPTER X 
DISCUSSION 
X. A. Main Study Findings 
 In this small cross-sectional study of women age 18-30, we found no evidence of 
an association between selective serotonin reuptake inhibitor (SSRIs) use and bone 
mineral density (BMD) or bone mineral content (BMC). There was also no evidence of 
an association between history of depression and BMD.  While users of SSRIs did have a 
lower mean BMD compared to non-users, the difference was very modest and not 
statistically significant.   
 We believe that the null results of our study are likely due to the lack of power, 
the potential for non-differential misclassification of the exposure, and residual 
confounding by depression.   Our initial power calculations revealed the need of at least 
30 users of SSRIs in order to see a mean difference in BMD of 0.1g/cm² between groups. 
However, only 13 women (5%) reported use of SSRIs, and mean difference of 0.01g/cm² 
was seen.  Increasing the sample size of our population would have led to increased 
power and perhaps evidence of an inverse association between SSRI use and bone 
mineral density would have been revealed.   
 There may have been some non-differential misclassification of the exposure in 
this study which may have biased our results toward the null.  We were limited by the use 
of self-report questionnaires to determine the exposure, and even further limited by 
asking only one question concerning SSRI use.  Further more; we had no information on 
dose, duration of use, or reason for use.  Information on dose and duration would have 
allowed us to conduct stratified analysis and assess the temporality of the association.  
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We did not have the ability to confirm or validate the self-report use of SSRIs in the 
women. As a result the women may have been incorrectly classified as users or non-users 
of SSRIs.  Finally, if we collected information on reason for use we would have been able 
to separate the effects of important confounders, most importantly depression, and 
adjusted accordingly.  
 The potential effects of residual confounding by depression are outlined below.  
X. B. Consistency With Literature 
 Since this is the first study to examine the relationship between SSRI use and 
BMD in a young, healthy, and premenopausal women we cannot compare our findings to 
those of prior studies.  However, our study results are consistent with one of the 
previously published studies examining the relationship between SSRI use and BMD in 
older postmenopausal women.  In their prospective cohort design study, Spangler et al. 
found no association between SSRI use and 3 year changes in site specific BMD18 [.003 
(-0.0005 to .0069) p=0.09], [.002 (-.0031 to .0078) p=0.40], [.003 (-0.0007 to .0073) p= 
0.10] in hip BMD, spine BMD, and total body BMD, respectively, compared with 
nonusers.  
 In the study most similar to ours with regards to cross-sectional study design, 
population size, and premenopausal status, Williams et al.22 found a lower mean percent 
of BMD at all sites measured:  femoral neck was 5.6% lower, [0.977 (0.116) vs. 0.922 
(0.117) p=0.03], trochanter was 6.2% lower, [0.813 (0.105) vs. 0.763 (0.107) p=0.04], 
and mid forearm was 4.4% lower, [0.745 (0.007) vs. 0.712 (0.068) p=0.03].  In contrast, 
in our study, we found no evidence of a relationship between SSRI use and bone mineral 
density or bone mineral content.    
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X. C. Study Limitations 
X. C. 1 Nondifferential Misclassification of Exposure 
 SSRI use was measured using a self-report questionnaire, administered by a single 
trained interviewer at one study location, and assessed simultaneously with outcome.  
The participants answered only a single question related to SSRI use, and were not asked 
to bring in the prescription bottles or name the specific SSRI used.  Some participants 
may not have known which type of antidepressant they take, and thus misreported SSRI 
use, or they may not be willing to admit they take any antidepressants due to social 
stigma.  Likewise, some women may have inadvertently answered “yes” to the SSRI 
question.  They may have been using MAOI’s or another psychotropic medication not 
known the difference in the types.  This may have lead to nondifferential 
misclassification of the exposure, or misclassification between users and non-users of 
SSRI.  This misclassification would have biased our results toward the null.  
 In order to prevent misclassification in this study we asked only about current 
SSRI use.  Current use is easier to recall compared to ever or past use. Even with this 
restriction it is possible that non-differential misclassification of the exposure occurred, 
though we expect the impact of the misclassification to be modest.   
X. C. 2 Nondifferential Misclassification of the Outcome 
 The outcomes of the study, BMD and BMC, were measured using total body 
DEXA scans.  DEXA scans are a highly precise method of ascertaining total body BMD 
and BMC and results are highly correlated with those from site specific DEXA scans.14 
The DEXA scanner used was calibrated daily following manufacturer instructions and all 
scans were analyzed with the included software. 25 The scans were also performed by two 
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technicians who did not know the disease or exposure status of the participants. 25 
However, it is possible that some imprecision in the DEXA scanner was present and this 
resulted in inaccurate measures.  If this non-differential misclassification did occur then 
our results would be biased towards the null.  However, given the precision of the 
techniques used in the study to ascertain outcome we believe that the likelihood of 
nondifferential misclassification of the outcome was low and the impact minimal.   
X. C. 3 Confounding 
 Confounding was accounted for in the study by adjusting for known covariates 
previously noted in the literature.  Because information on potential confounders was 
collected using self-report questionnaires, we may have some residual confounding in the 
study.  For instance, we collected information on physical activity, which we assessed as 
a potential confounder of the relationship between SSRI use and BMD.  Physical activity 
was a significant predictor of BMD and BMC in this population.  If women who take 
SSRIs were more likely to have significantly different levels of physical activity 
compared to the non-users then our results would be overestimated.  It is possible that our 
questionnaire failed to collect accurate information on physical activity leading to a 
miscalculation of the MET hours/week variable and resulting in residual confounding 
even after adjusting for it in the model.   
 Previous studies have hypothesized an association between depression and bone 
health; therefore we felt it important to consider its role in our study.5, 15, 22, 23 In addition,  
depression is inversely associated with BMD through several mechanisms including: 
vitamin D metabolism, diet, and behavioral factors.  We collected information on history 
of depression from the participants via a self-report questionnaire.  After evaluation of 
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history of depression in our initial models, we found it to be significantly associated with 
SSRI use however, due to small numbers of women reporting depression and even 
smaller numbers reporting SSRI use, there was no evidence that history of depression 
was associated with BMD in our study.   
We did not collect information on the reason SSRIs were prescribed.  If SSRIs 
were prescribed for a medical condition independently associated with BMD, such as 
anorexia nervosa, 16 or depression and if this condition was positively associated with 
SSRI use then it is possible that not including this as a confounder would overestimate 
our results.  We believe that the impact of this in our study was minimal due to the 
overall null finding of the study.   
X. C. 4 Selection Bias 
 Selection bias in this study would exist if women with low BMD who take SSRIs 
were more likely to participate in the study than the participants who used SSRIs and did 
not have low BMD or those who did not use SSRIs with low BMD or those who did not 
use SSRIs and did not have low BMD. It is possible that women who are taking SSRIs 
and have low BMD are more likely to visit their physician, because of these conditions 
and are therefore more likely to encounter an advertisement for the study.  If these 
women were more likely to enroll in the study then this would result in an overestimation 
of the SSRI users/low BMD cell.  This is selection bias and if it occurred it would lead to 
an overestimation of the risk. The magnitude of selection bias in our study is likely to be 
low, due to the rarity of low BMD in this population of women who are at peak BMD 
and the likelihood that most women are not aware of their BMD.   
 
 27 
 
X. C. 5 Information Bias 
 One potential source of information bias in our study was surveillance bias.  If 
bone mineral density or bone mineral content was assessed differently between users and 
non-users of SSRIs then this may lead to information bias.  We do not feel that this 
affected our study due to the accuracy of the DEXA scanner.  The technicians 
administering the scans were both blinded to whether or not the participant used SSRIs.  
Both were also highly trained in the maintenance and operation of the scanner.  However, 
it is possible that the machine has some error associated with its measurement and 
reporting of BMD or BMC. This error would have been randomly distributed between the 
users and non-users of SSRIs.   
X. C. 6 Temporal Issues 
 In this study we are evaluating whether SSRI use was associated with lower 
BMD; however it may be possible that lower BMD led to SSRI use.  Women who have a 
lower mean BMD may become depressed due to their condition and therefore use SSRIs.  
We do not believe temporal issues will affect our study because women were likely not 
aware of their BMD status.   
X. C. 7 Survivor Bias 
 For our study, if those with lower mean BMD who have the highest level of SSRI 
use are more likely to die of the inverse changes to their BMD due to the level of 
exposure and if these women die before we can enroll them in the study then the 
diseased/user cell is decreased and our results would be underestimated.  This is highly 
unlikely in this study because at this age range, a change to BMD or BMC is not fatal. 
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Most notably, our population of young women has not had enough time to develop severe 
or life threatening forms of the condition, such as osteopenia or osteoporosis.  
X. C. 8 Generalizability 
 This study is generalizable to women who use the same formulations of SSRIs 
found in this country.  Different formulations of SSRIs found outside the U.S. may not 
have the same effect on BMD or BMC as the formulation in the U.S.  This study may 
also not be generalizable to men.  The physiological mechanism of SSRIs affect BMD or 
BMC may differ between men and women.  
X. D. Study Conclusion 
 In this study there was no evidence of a statistically significant relationship 
between SSRI use by young, premenopausal women aged 18-30 and BMD. Because 
the use of SSRI medications remains high in the general population any potential 
adverse affects should be examined.  Further research should include larger cross-
sectional studies and prospective cohort studies. In order to maximize power to 
examine the relationship it may be necessary to over sample from women with a 
history of depression.   
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APPENDIX 
 
TABLES 
Continuous Variables N Mean SD minimum maximum
Age (years) 254 21.7 4.3 18 69.9
Physical Activity Level (METs/wk) 248 176.6 69.7 63.5 403
Body Mass Index (kg/m²) 256 23 3.3 16.7 37.8
Calcium Intake (mg/day) 237 1196.1 565.5 128.8 4600.6
Vitamin D Intake (IU/day) 237 380.2 298 3.4 1806.1
Catergorical Variables N %
Parity 
yes 8 3.1
no 247 96.9
Alcohol use 
none/light 135 52.7
moderate 61 23.8
heavy 60 23.4
Current OC use 
yes 109 42.6
no 147 57.4
Current Smoker 
yes 15 5.9
no 240 94.1
Race 
White 219 85.9
other 36 14.1
History of Depression
yes 33 12.9
no 223 87.1
Age at menarche
<14 202 78.9
>14 54 21.1
Calcium (mg/day)
low 200 78.1
moderate 53 20.7
high 3 1.2
Vitamin D (IU/day)
low 217 84.8
moderate 35 13.7
high 4 1.6
Vitamin D (IU/day)
<100 57 22.3
>100 199 77.7
Table 1: Characteristics of UMass Vitamin D Status Study Population, Selective Serotonin Reuptake 
Inhibitor Use and Bone Mineral Density g/cm²,UMass Vitmain D Status Study, 2006-201, N=256
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N %
13 5.08
243 94.92
Yes
No
Table 2. Distribution of Selective 
Serotonin Reuptake Inhibitor Use; UMass 
Vitamin D Status Study, 2006-2011
SSRI use
 
 
 
Bone Measurement N Mean SD Minimum Maximum Missing
aBMD (g/cm²)* 246 1.16 0.08 0.97 1.4 10
BMC (grams)** 246 2541.5 349.2 1833 3682 10
*bone mineral density
**bone mineral content
Table 3: Distribution of Bone Mineral Density and Bone Mineral Content, UMass Vitamin D 
Status Study, 2006-2011, N= 246
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Yes No
Mean (SD) Mean (SD) P value
Age (years) 21.6 (3.3) 21.7 (4.3) 0.93
Body Mass Index (kg/m²) 24.9 (5.1) 22.9 (3.2) 0.19
Physical Activity (METs/wk) 156.0 (49.4) 177.7 (70.6) 0.27
Calcium Intake (mg/day) 1166.1 (372.4) 1197.6 (574.5) 0.85
Vitamin D Intake (IU/day) 400.9 (290.2) 379.1 (298.9) 0.81
Categorical Variables Yes,  N (%) No,  N(%) P value**
Parity 0.99
yes 0 (0) 8 (3.1)
no 13 (5.1) 234 (91.8)
Alcohol use (g/day) 0.28
none/light 7 (2.7) 128 (50)
moderate 5 (2.0) 56 (21.9)
heavy 1 (1.4) 59 (23.1)
Current OC use 0.47
yes 4 (1.6) 105 (41.0)
no 9 (3.5) 138 (53.9)
Current smoker 0.99
yes 0 (0) 15 (5.9)
no 13 (5.1) 227 (89.0)
Race 0.7
white 12 (4.7) 207 (81.2)
other 1 (0.4) 35 (13.7)
Calcium Intake (mg/day)*** 0.78
low 10 (3.9) 190 (74.2)
moderate 3 (1.2) 50 (19.5)
high 0 (0) 3 (1.2)
Vitamin D Intake (IU/day)*** 0.51
low 10 (3.9) 207 (80.9)
moderate 3 (1.2) 32 (12.5)
high 0 (0) 4 (1.6)
Vitamin D level (IU/day) 0.74
<100 2(0.8) 55 (21.5)
>100 11 (4.3) 188 (73.4)
History of Depression <0.001
yes 11 (4.3) 22 (8.6)
no 2 (0.8) 221 (86.3) 
Age at Menarche (years) 0.31
<14 12 (4.7) 190 (74.2)
>14 1 (0.4) 53 (20.7) 
*two-sided ttest
**Fisher's Exact Test
***Categorical Levels
Table 4: Distribution of Covariates According to Selective Serotonin Reuptake 
Inhibitor Use: UMass Vitamin D Status Study, 2006-201, N=246
SSRI Use 
Continuous Variables* 
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Continuous Variables* β SE P value
Age (years) 0.0004 0.001 0.72
Body Mass Index (kg/m²) 0.009 0.0014 <.0001
Physical Activity (METs/wk) 0.0002 0.00007 0.0007
Calcium Intake (mg/day) 0.000005 0.000009 0.56
Vitamin D Intake (IU/day) 0.00002 0.0000017 0.22
Categorical Variables* Mean (SD) β SE r² P value 
Parity
yes 1.14 ( 0.08) -0.02 0.03 0.003 0.42
no 1.16 (0.08)
Alcohol use (g/day)
none/light 1.16 ( 0.08) -0.0003 0.006 0.000009 0.13
moderate 1.18 (0.08)
heavy 1.15 (0.07)
Current OC use
yes 1.16 (0.07) 0.007 0.01 0.002 0.51
no 1.16 (0.08)
Current smoker
yes 1.16 (0.06) -0.002 0.02 0.00006 0.9
no 1.16 (0.08) 
Race 
white 1.16 (0.08) 0.01 0.01 0.003 0.43
other 1.17 (0.08)
Calcium Intake (mg/day)
low 1.16 (0.08) 0.008 0.01 0.003 0.35
moderate 1.17 (0.08)
high 1.12 (0.05)
Vitamin D Intake (IU/day)
low 1.16 (0.08) 0.016 0.01 0.007 0.29
moderate 1.18 (0.09)
high 1.16 (0.08)
Vitamin D level (IU/day)
<100 1.16 (0.08) 0.004 0.01 0.0005 0.73
>100 1.16 (0.08)
History of Depression
yes 1.17 (0.08) 0.02 0.01 0.005 0.29
no 1.16 (0.08) 
Age at Menarche (years)
<14 1.16 (0.08) -0.01 0.01 0.005 0.29
>14 1.15 (0.08)
*one predictor linear regression
Table 5: Change in Bone Mineral Density (Beta, SE) in g/cm² Associated with Covariates: UMass 
Vitamin D Status Study 2006-201, N=246
BMD
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Continuous Variables* β SE P value
Age (years) 2.15 7.47 0.77
Body Mass Index (kg/m²) 45.62 6.12 <.0001
Physical Activity (METs/wk) 0.8 0.33 0.02
Calcium Intake (mg/day) 0.005 0.04 0.22
Vitamin D Intake (IU/day) 0.07 0.08 0.4
Categorical Variables* Mean (sd) β SE r² P value 
Parity
yes 2457 (428) -86.57 125.64 0.002 0.49
no 2544 (346)
Alcohol use (g/day)
none/light 2533 (368) -1.39 27.08 0 0.96
moderate 2582 (347)
heavy 2519 (305)
Current OC use
yes 2535 (323) -10.67 45.15 0.0002 0.81
no 2546 (368)
Current smoker
yes 2459 (214) -88.03 93.05 0.004 0.35
no 2547 (356)
Race 
white 2541 (336) 4.04 63.86 0 0.94
other 2545 (426)
Calcium Intake (mg/day)
low 2519 (334) 0.05 0.04 0.007 0.22
moderate 2622 (399)
high 2615 (273)
Vitamin D Intake (IU/day)
low 2529 (340) 58.13 53.33 0.005 0.28
moderate 2619 (400) 
high 2525 (369)
Vitamin D level (IU/day)
<100 2521 (338) 26.08 53.51 0.001 0.63
>100 2547 (353)
History of Depression
yes 2600 (361) 67.58 66.17 0.0043 0.31
no 2533 (347)
Age at Menarche (years)
<14 2543 (352) -8.73 55.02 0.0001 0.87
>14 2535 (343)
* single predictor linear regression
Table 6: Change in Bone Mineral Content (Beta, SE) in grams Assoicated With Covariates: 
UMass Vitamin D Status Study 2006-201, N=246
BMD
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BMD (g/cm²) SSRI Use N Mean SD Min Max Median Range 
Yes 12 1.16 0.06 1.07 1.28 1.15 0.21
No 234 1.17 0.08 0.97 1.38 1.16 0.41
BMC (g) SSRI Use N Mean SD Min Max Median Range 
Yes 12 2549 285 1992 2974 2540 982
No 234 2541 353 1833 3682 2514 1849
Table 7:Distribution of Bone Mineral Density (g/cm²) and Bone Mineral Content (grams) by level 
of Selective Serotonin Reuptake Inhibitor Use; UMass Vitamin D Status Study, 2006-2011, N=246
 
 
 
BMD (g/cm²) Mean (SD)+
Unadjusted β 
(SE) P value
Age Adjusted β 
(SE) P value
Fully Adjusted β 
(SE)* P value
SSRI Use 1.15(0.07) 0.006(0.02) 0.78 0.006 (0.02) 0.78 -0.0094 (0.02) 0.66
SSRI No Use 1.16 (0.07)
BMC (g) Mean (SD)+
Unadjusted β 
(SE) P value
Age Adjusted β 
(SE) P value
Fully Adjusted β 
(SE)* P value
SSRI Use 2467 (316) 8.35 (103.56) 0.94 10.35 (103.63) 0.92 -80.43 (95.03) 0.39
SSRI No Use 2548 (316)
Table 8: Crude and Adjusted Association of Selective Serotonin Reuptake Inhibitor Use and Bone Mineral Density 
(g/cm²) and Bone Mineral Content (g), UMass Vitamin D Status Study, 2006-2011, N=246
 +Least Squares adjusted for age, bmi, and physical activity
*adjusted for age, BMI, and physical activity
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N (%) Mean (SD) Min Max Median Range P value*
33 (12.89) 1.17 (0.08) 1.04 1.36 1.16 0.32 0.29
223 (87.1) 1.16 (0.08) 0.97 1.38 1.16 0.41
N (%) Mean (SD) Min Max Median Range P value*
33 (12) 2600 (361) 1992 3322 2546 1330 0.31
223 (87) 2532 (347) 1833 3682 2510 1330
BMD g/cm²
History of Depression
No History of Depression
Table 9:Crude and Adjusted Association of History of Depression and  Bone Mineral Density (g/cm²) and Bone 
Mineral Content (grams); Umass Vitamin D Status Study, 2006-2011, N=246
BMC (g)
History of Depression
No History of Depression
* Two sided T test
 
 
 
β SE r² Pr(t)
BMD (g/cm²) 0.015 0.015 0.005 0.29
BMC (g) 67.58 66.17 0.0043 0.31
Table 10: Relation of Bone Mineral Density (g/cm²) and Bone Mineral 
Content (grams) and History of Depression; Umass Vitamin D Status 
Study, 2006-2011, N=246
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